TOP STORIES

• REGULATORY Japan Approves Enhertu’s NSCLC Use, More Label Expansions
  August 24, 2023

• REGULATORY Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
  August 23, 2023

• REGULATORY Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
  August 23, 2023

• REGULATORY Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
  August 22, 2023

• REGULATORY MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
  August 21, 2023

• BUSINESS Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
  August 18, 2023

• BUSINESS Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
  August 17, 2023

• REGULATORY Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
  August 16, 2023

• BUSINESS Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
  August 14, 2023

• REGULATORY Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
  August 10, 2023

• REGULATORY Japan Sees Delay in Pilot-Based Revenue Assurance System for Antibiotics, Criteria Still Up in Air
  August 9, 2023

• BUSINESS Astellas Puts Up US$50 Million for CAR-T Player Poseida
  August 9, 2023

• REGULATORY Approve 16 Pediatric Cancer Meds as Exceptional Step Beyond Law, Oncologist Urges
  August 8, 2023

• BUSINESS Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
  August 8, 2023

• REGULATORY MHLW Panel to Review Alzheimer’s Med Lecanemab on August 21
  August 8, 2023

• COMMENTARY Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
  August 7, 2023

• REGULATORY Japan Adopts New Evaluation Method for Nitrosamine Impurities Risks
  August 7, 2023

• BUSINESS Mitsubishi Tanabe Aims to Maximize Value of Mounjaro through Synergies with Other Products
  August 4, 2023

• REGULATORY Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
  August 3, 2023

• BUSINESS Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
  August 3, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• 57
• …
• Next ›
• 最終 »